OGS Partners with NeoGenesis to Identify Lead Compounds for OGS Proteins | GenomeWeb

NEW YORK, June 20 - Oxford Glycosciences and NeoGenesis have agreed to partner in an effort to identify small molecule drugs for OGS' protein targets, the companies said Wednesday. 

OGS, of Oxford, UK, will provide an undisclosed number of protein targets to NeoGenesis, and pay NeoGenesis research fees, milestone payments, and royalties for lead compounds that the company identifies. OGS will commercialize any lead compounds, and is also making an undisclosed equity investment in NeoGenesis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.